DnB Asset Management AS Grows Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

DnB Asset Management AS boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 39.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,619 shares of the medical research company’s stock after buying an additional 22,450 shares during the quarter. DnB Asset Management AS’s holdings in IQVIA were worth $15,646,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in IQV. denkapparat Operations GmbH purchased a new stake in IQVIA in the 4th quarter worth about $215,000. Pictet Asset Management Holding SA raised its holdings in shares of IQVIA by 12.7% in the fourth quarter. Pictet Asset Management Holding SA now owns 105,227 shares of the medical research company’s stock worth $20,678,000 after buying an additional 11,839 shares during the period. Broadway Wealth Solutions Inc. bought a new stake in shares of IQVIA during the 4th quarter worth approximately $274,000. New Age Alpha Advisors LLC bought a new position in IQVIA in the 4th quarter valued at $4,565,000. Finally, Providence Capital Advisors LLC increased its stake in IQVIA by 0.8% in the fourth quarter. Providence Capital Advisors LLC now owns 22,264 shares of the medical research company’s stock worth $4,375,000 after purchasing an additional 173 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Robert W. Baird dropped their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Finally, BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Trading Down 1.2 %

Shares of NYSE:IQV opened at $177.27 on Friday. The business’s 50-day moving average is $193.15 and its 200 day moving average is $206.47. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $176.03 and a 1 year high of $253.84. The firm has a market capitalization of $31.25 billion, a P/E ratio of 23.64, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.